Intravitreal Aflibercept

ApprovedProtein / enzyme

Intravitreal Aflibercept is one of 171 small molecule programs targeting Proliferative Diabetic Retinopathy. It is currently in Approved.

Indications

Total Trials

Active Trials

170

Competitors

Pipeline

Status by Indication[3][1]

Indication

Proliferative Diabetic RetinopathyActive, not recruiting

RetinopathyActive, not recruiting

Macular DegenerationActive, not recruiting

Retinal Vein OcclusionActive, not recruiting

Polypoidal Choroidal VasculopathyActive, not recruiting

Diabetic Macular EdemaActive, not recruiting

Diabetic RetinopathyActive, not recruiting

Age-Related Macular DegenerationActive, not recruiting

Proliferative VitreoretinopathyActive, not recruiting

Proliferative Diabetic RetinopathyPhase 2

Active, not recruiting

RetinopathyPhase 2

Active, not recruiting

Macular DegenerationPhase 2

Active, not recruiting

Retinal Vein OcclusionApproved

Active, not recruiting

Polypoidal Choroidal VasculopathyApproved

Active, not recruiting

Diabetic Macular EdemaPhase 2

Active, not recruiting

Diabetic RetinopathyPhase 2

Active, not recruiting

Proliferative VitreoretinopathyPhase 2

Active, not recruiting

Competition

Competitive Landscape

237 competitors in Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

Lucentis

Roche

Phase 3

64 2

Eylea

Regeneron

Phase 3

44 3

Vabysmo

Roche

Phase 3

13 4

Beovu

Novartis

Phase 3

10 5

Macugen

Pfizer

Phase 3

6 6

Avastin

BBio-Thera Solutions

Phase 3

18 7

Intravitreal Aflibercept

Regeneron

Approved

4 8

Retaane

AAlcon Research

Phase 3

5 9

Kenalog

BBausch Health Americas, Inc.

Phase 3

2 10

Forzinity

SStealth BioTherapeutics Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diabetic Macular Edema4 trials

A Pharmacokinetic stuDy of intRavitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Diabetic Macular Edema

Withdrawn·SStanford University·Phase 2·NCT04588948

Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)

Completed· Regeneron logo

Regeneron·Phase 1·NCT01997164·20 enrolled

Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema

Completed· Regeneron logo

Regeneron·Phase 2·NCT02712008·302 enrolled

Show 1 more trial

Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema

Completed· Regeneron logo

Regeneron·Phase 3·NCT01363440·466 enrolled

Age-Related Macular Degeneration4 trials

Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)

Completed· Regeneron logo

Regeneron·Phase 3·NCT00964795·323 enrolled

Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)

Completed· Regeneron logo

Regeneron·Phase 4·NCT01722045·154 enrolled

Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept

Unknown status·TTennessee Retina·Phase 4·NCT03468296·22 enrolled

Show 1 more trial

Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)

Terminated· Regeneron logo

Regeneron·Phase 2·NCT02418754·505 enrolled

Polypoidal choroidal vasculopathy3 trials

Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy

Completed·AAssociation for Innovation and Biomedical Research on Light and Image·Phase 4·NCT02495181·50 enrolled

Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation

Completed·UUnknown Sponsor·Phase 4·NCT01871376·25 enrolled

Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment

Completed·FFondation Ophtalmologique Adolphe de Rothschild·N/A·NCT02381730·37 enrolled

Proliferative Diabetic Retinopathy3 trials

Aflibercept Injection for Proliferative Diabetic Retinopathy

Completed·UUniversity of Oklahoma·Phase 2·NCT01805297·12 enrolled

Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study

Completed·OOphthalmic Consultants of Long Island·Phase 2/3·NCT01813773·20 enrolled

Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)

Completed· Regeneron logo

Regeneron·Phase 3·NCT02718326·402 enrolled

Outcome2 trials

Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept

Unknown status·UUnity Health Toronto·Phase 4·NCT03056079·168 enrolled

Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV

Completed·KKim's Eye Hospital··NCT05662943·135 enrolled

11 more indications

Macular Degeneration2 trials

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection

Completed· Regeneron logo

Regeneron·Phase 2·NCT02713204·365 enrolled

Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration

Completed·MMidAtlantic Retina·N/A·NCT01773954·40 enrolled

DME2 trials

Variable Interval Versus Set Interval Aflibercept for DME

Completed·CCalifornia Retina Consultants·Phase 4·NCT02392364·50 enrolled

DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact

Completed· Regeneron logo

Regeneron·Phase 2·NCT00789477·221 enrolled

Retinal Vein Occlusion2 trials

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

Completed· Regeneron logo

Regeneron·Phase 3·NCT01521559·183 enrolled

Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion

Unknown status·YYeungnam University College of Medicine·Phase 4·NCT03405376·49 enrolled

Retinopathy2 trials

Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy

Completed·—·Phase 2·NCT01971190·43 enrolled

The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy

Completed·WWills Eye·Phase 2·NCT01710332·12 enrolled

Diabetic Retinopathy1 trial

The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy

Completed·—·Phase 2·NCT03006081·38 enrolled

Age-Related Maculopathy1 trial

Change in Ocular Perfusion After Intravitreal Anti-VEGF in Patients with Age-related Maculopathy or Diabetic Macula Edema

Completed·AAugenabteilung Allgemeines Krankenhaus Linz··NCT06878573·36 enrolled

MPA1 trial

Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion

Completed·OOphthalmic Consultants of Boston·Phase 1/2·NCT01724554·24 enrolled

Neovascular AMD1 trial

IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD

Completed·JJeffrey S Heier·Phase 2·NCT02462889·128 enrolled

Proliferative Vitreoretinopathy1 trial

Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair

Unknown status·—·Phase 2·NCT04580147·150 enrolled

Aged1 trial

Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab

Withdrawn·SSoutheast Clinical Research Associates, LLC·Phase 4·NCT03059277

Unspecified3 trials

Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe

Completed· Regeneron logo

Regeneron·Phase 4·NCT03767738·65 enrolled

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection

Completed·UUniversity of California, San Diego·Phase 4·NCT02689518·50 enrolled

Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results

Unknown status·RRetina Research Institute, LLC·Phase 4·NCT01657669·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 33 trial records for Intravitreal Aflibercept. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intravitreal Aflibercept compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intravitreal Aflibercept. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Approved[1]
Company: Regeneron

Intravitreal Aflibercept

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diabetic Macular Edema4 trials

Age-Related Macular Degeneration4 trials

Polypoidal choroidal vasculopathy3 trials

Proliferative Diabetic Retinopathy3 trials

Outcome2 trials

Macular Degeneration2 trials

DME2 trials

Retinal Vein Occlusion2 trials

Retinopathy2 trials

Diabetic Retinopathy1 trial

Age-Related Maculopathy1 trial

MPA1 trial

Neovascular AMD1 trial

Proliferative Vitreoretinopathy1 trial

Aged1 trial

Unspecified3 trials

References

Drug Info

Quick Facts

Related News